Key Drivers
- Strong Liquidity
- No Revenue
- Ongoing Cash Burn
AIAI Summary
CAPR is no longer a financing-survival story but a cash-backed, near-term FDA binary on deramiocel, where approval quality—not solvency—is the key driver; the trade now hinges on whether the August decision and label breadth can overcome weak price action, legal friction, and commercialization risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Ongoing Cash Burn
CAPR has an exceptionally strong, lightly levered balance sheet, but no revenue, persistent losses, and heavy cash burn make fundamentals weak and valuation expensive.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Fragile support
- •Overhead supply
Over the last month, CAPR has rolled over from about $30.40 to $23.21 in a clear downtrend, with $23.00-$23.20 as fragile support and $24.08/$25-$26 now acting as overhead resistance until buyers reclaim those levels. ക
Brief peak near $30.40 was followed by a sharp selloff
Sentiment & News
Key News Insights:
- •Drill momentum
- •FDA progress
- •Price weakness
Caprock Mining paired a small financing close with strong gold drill results and insider buying, while Capricor Therapeutics advanced deramiocel toward key FDA and conference milestones despite recent share weakness.
Caprock's news flow is supportive for exploration sentiment, while Capricor's regulatory and data updates are constructive but may need clearer market confirmation to lift the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings